Agustín Julián-Jiménez

Dr. Agustín Julián-Jiménez


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2014 in Enfermedades Infecciosas y Microbiología Clínica
Verified
Journal Article
Closed access
AJAgustín Julián-Jiménez
Agustín Julián-Jiménez
FCFrancisco Javier Candel
Francisco Javier Candel
JCJuan González del Castillo
Juan González del Castillo


1 April 2014 in Enfermedades Infecciosas y Microbiología Clínica
Verified
Journal Article
Closed access
AJAgustín Julián-Jiménez
Agustín Julián-Jiménez
JZJesús Timón Zapata
Jesús Timón Zapata
ELEmilio J Laserna-Mendieta
Emilio J Laserna-Mendieta
ISIsabel Sicilia-Bravo
Isabel Sicilia-Bravo
MRMaría José Palomo-De Los Reyes
María José Palomo-De Los Reyes
RCRafael Cuena-Boy
Rafael Cuena-Boy

1 June 2013 in Archivos de Bronconeumología
Verified
Journal Article
Closed access
AJAgustín Julián-Jiménez
Agustín Julián-Jiménez
MRMaría José Palomo de Los Reyes
María José Palomo de Los Reyes
RMRaquel Parejo Miguez
Raquel Parejo Miguez
NLNatividad Laín-Terés
Natividad Laín-Terés
RCRafael Cuena-Boy
Rafael Cuena-Boy
ALAgustín Lozano-Ancín
Agustín Lozano-Ancín

1 March 2019 in Neurología
Verified
Journal Article
Open access
AJAgustín Julián-Jiménez
Agustín Julián-Jiménez
MMM.I. Morales-Casado
M.I. Morales-Casado
The classic clinical presentation of bacterial meningitis (BM) is observed in less than half of the cases in adults, and symptoms are less specific in children, the elderly or immunocompromised, and other chronic patients. The usual signs and symptoms do not provide optimal sensitivity and specificity for distinguishing possible BM from viral meningitis (VM), which may lead to a delay in the appropriate antimicrobial therapy. Society therefore stands to benefit from the development of effective, objective, and rapid tools able to predict and identify patients with BM. These tools include laboratory tests for blood and cerebrospinal fluid (CSF). The aim of this review is to summarise recently published scientific evidence in order to clarify existing controversies and compare the usefulness and diagnostic ability of the different parameters used to predict BM. Systematic search of the main bibliographic databases and platforms to identify articles published between January 2000 and January 2016. We selected 59 articles that meet the objectives of this review. CSF lactate, proportion of polymorphonuclear leukocytes, and CSF glucose, as well as serum procalcitonin (PCT), are the independent factors most predictive of bacterial aetiology. The model that combines serum PCT and CSF lactate achieves the highest predictive power for BM, with a sensitivity and specificity exceeding 99%. We should consider BM when CSF lactate >33 md/dL and/or PCT>0.25ng/mL.

30 October 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
FCFrancisco Javier Candel
Francisco Javier Candel
MLMiguel Salavert Lleti
Miguel Salavert Lleti
MBMiren Basaras
Miren Basaras
MBMarcio Borges
Marcio Borges
RCRafael Canton
Rafael Canton
LSLeyre Serrano
Leyre Serrano
Community-acquired pneumonia represents the third-highest cause of mortality in industrialized countries and the first due to infection. Although guidelines for the approach to this infection model are widely implemented in international health schemes, information continually emerges that generates controversy or requires updating its management. This paper reviews the most important issues in the approach to this process, such as an aetiologic update using new molecular platforms or imaging techniques, including the diagnostic stewardship in different clinical settings. It also reviews both the Intensive Care Unit admission criteria and those of clinical stability to discharge. An update in antibiotic, in oxygen, or steroidal therapy is presented. It also analyzes the management out-of-hospital in CAP requiring hospitalization, the main factors for readmission, and an approach to therapeutic failure or rescue. Finally, the main strategies for prevention and vaccination in both immunocompetent and immunocompromised hosts are reviewed.